Search
Quinagolide
go.drugbank.com/drugs/DB09097ApprovedWithdrawnQuinagolide is currently available in several countries including Canada, but not approved for treatment in the United States. … These drugs are effective in patients who are intolerant or resistant to [DB01200].
Synonyms: (+-)-N,N-Diethyl-N'-((3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamideProducts: Norprolac 0,025 mg u. 0,050 mg - Tabletten (Startpackung), NORPROLAC® 0.025 MGRisankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigational[L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.
Categories: Skin and Mucous Membrane AgentsProducts: Skyrizi 75 mg solution for injection in pre-filled syringe, SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/MLLanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigational[A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018. … [L4538] It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells.
Categories: Drugs Used in Hereditary AngioedemaProducts: TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 2 ADETAsfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). … Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved
Products: STRENSİQ 18 MG/0.45 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET, STRENSİQ 28 MG/0.7 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADETCalcitriol
go.drugbank.com/drugs/DB00136ApprovedInvestigationalNutraceuticalIt is produced in the body after series of conversion steps of 7-dehydrocholesterol from exposure to UV light. 7-dehydrocholesterol is converted to [DB00169] (vitamin D3) in the skin, which is then converted … to [DB00146] in the liver and kidneys.
Categories: Skin and Mucous Membrane AgentsProducts: CALCITRIOLO EG, QALYVİZ 0.5 MCG YUMUŞAK KAPSÜL, 100 ADETMethylene blue
go.drugbank.com/drugs/DB09241ApprovedInvestigationalHistorically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. … Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early
Mixtures: UR N-C Urinary Antiseptic, Me NaPhos MB Hyo 1Products: BLUMET 100 MG/10 ML IV ENJEKSIYON IÇIN ÇÖZELTI IÇEREN AMPUL ,1 AMPUL, BLUMET 50 MG/5 ML IV ENJEKSIYON IÇIN ÇÖZELTI IÇEREN AMPUL ,1 AMPULTolmetin
go.drugbank.com/drugs/DB00500ApprovedA non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin.
Products: Tolectin 200 Tab 200mg, Tolectin 400 Cap 400mgNitroprusside
go.drugbank.com/drugs/DB00325ApprovedInvestigationalNitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing...
Categories: Compounds used in a research, industrial, or household setting, Arteriolar Smooth Muscle, Agents Acting OnProducts: Sodium Nitroprusside In 0.9% Sodium Chloride, N-PRUSSomapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigational[A219146] Somapacitan was granted FDA approval on 28 August 2020.[L15666] … [A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.
Products: Sogroya® 5 mg/1.5 mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem (1 adet), Sogroya® 10 mg/1.5 mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem (1 adet)Sulodexide
go.drugbank.com/drugs/DB06271ApprovedInvestigationalWithdrawnSulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving heparin (FMH).
Products: ANJIOFLUX 600 LRU 2 ML ENJEKTABL COZELTI ICEREN 10 AMPUL, VESSEL DUE F 250 LSU CAPSULE